Patents by Inventor Lev Tyler Dewey Fanning

Lev Tyler Dewey Fanning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11884672
    Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: January 30, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Diane Boucher, Michael John Boyd, Michael Aaron Brodney, Michael Philip Clark, Veronique Damagnez, Lev Tyler Dewey Fanning, Robert Francis Fimognari, Gabrielle Simone Fleming, Kevin James Gagnon, Pedro Manuel Garcia Barrantes, Robert Daniel Giacometti, Simon Giroux, Ronald Lee Grey, Jr., Samantha Guido, Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Mei-Hsiu Lai, Siying Liu, Adam Looker, Brad Maxwell, John Patrick Maxwell, Ales Medek, Philippe Marcel Nuhant, Kirk Alan Overhoff, Setu Roday, Stefanie Roeper, Steven M. Ronkin, Rupa Sawant, Yi Shi, Muna Shrestha, Marisa Sposato, Kathy Stavropoulos, Rebecca Jane Swett, Timothy Lewis Tapley, Qing Tang, Stephen Thomson, Jinwang Xu, Mariam Zaky, Kevin Michael Cottrell
  • Publication number: 20240018161
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 18, 2024
    Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Andrew DINH, Timothy A. DWIGHT, Lev Tyler Dewey FANNING, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Paul KRENITSKY, Mark Thomas MILLER, Fabrice PIERRE, Alina SILINA, Joe A. TRAN, Lino VALDEZ, Jinglan ZHOU
  • Publication number: 20230382925
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.
    Type: Application
    Filed: October 6, 2021
    Publication date: November 30, 2023
    Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Timothy A. DWIGHT, Lev Tyler Dewey FANNING, Bryan A. FRIEMAN, Peter GROOTENHUIS, Anton V. GULEVICH, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Paul KRENITSKY, Vito MELILLO, Mark Thomas MILLER, Prasuna PARASELLI, Fabrice PIERRE, Alina SILINA, Joe A. TRAN, Johnny UY, Lino VALDEZ, Jinglan ZHOU
  • Publication number: 20230286907
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: December 13, 2022
    Publication date: September 14, 2023
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Nadia M. AHMAD, Corey ANDERSON, Vijayalaksmi ARUMUGAM, Iuliana Luci ASGIAN, Joanne Louise CAMP, Lev Tyler Dewey FANNING, Sara Sabina HADIDA RUAH, Dennis HURLEY, Yvonne SCHMIDT, David SHAW, Urvi PATEL, Stephen Andrew THOMSON, Lidio Marx CARVALHO MEIRELES
  • Publication number: 20230265080
    Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
    Type: Application
    Filed: February 9, 2023
    Publication date: August 24, 2023
    Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU, Kevin Michael COTTRELL
  • Patent number: 11623924
    Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: April 11, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Michael John Boyd, Diane M. Boucher, Michael Aaron Brodney, Veronique Damagnez, Lev Tyler Dewey Fanning, Mary Elizabeth Eccles, Robert Francis Fimognari, Jr., Kevin James Gagnon, Pedro M. Garcia Barrantes, Simon Giroux, Ronald Lee Grey, Jr., Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Joshua Kennedy Hussey, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Adam Looker, Brad D. Maxwell, John Patrick Maxwell, Ales Medek, Mettachit Navamal, Philippe Marcel Nuhant, Setu Roday, Stefanie Roeper, Rupa Sawant, Yi Shi, Rebecca Jane Swett, Qing Tang, Timothy Lewis Tapley, Stephen A. Thomson, Michael Waldo, Jinwang Xu, Kevin Michael Cottrell
  • Patent number: 11603351
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: March 14, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Nadia M. Ahmad, Corey Anderson, Vijayalaksmi Arumugam, Iuliana Luci Asgian, Joanne Louise Camp, Lev Tyler Dewey Fanning, Sara Sabina Hadida Ruah, Dennis Hurley, Yvonne Schmidt, David Shaw, Urvi Patel, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles
  • Publication number: 20210179587
    Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
    Type: Application
    Filed: October 4, 2019
    Publication date: June 17, 2021
    Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU
  • Publication number: 20210094906
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: March 19, 2020
    Publication date: April 1, 2021
    Inventors: Nadia M. Ahmad, Corey Anderson, Vijayalaksmi Arumugam, Iuliana Luci Asgian, Joanne Louise Camp, Lev Tyler Dewey Fanning, Sara Sabina Hadida Ruah, Dennis Hurley, Yvonne Schmidt, David Shaw, Urvi Patel, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles
  • Publication number: 20200361939
    Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.
    Type: Application
    Filed: May 13, 2020
    Publication date: November 19, 2020
    Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Diane BOUCHER, Michael John BOYD, Michael Aaron BRODNEY, Michael Philip CLARK, Veronique DAMAGNEZ, Lev Tyler Dewey FANNING, Robert Francis FIMOGNARI, Gabrielle Simone FLEMING, Kevin James GAGNON, Pedro Manuel GARCIA BARRANTES, Robert Daniel GIACOMETTI, Simon GIROUX, Ronald Lee GREY, Jr., Samantha GUIDO, Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., Peter Jones, Sarathy KESAVAN, Mei-Hsiu LAI, Siying LIU, Adam LOOKER, Brad MAXWELL, John Patrick MAXWELL, Ales MEDEK, Philippe Marcel NUHANT, Kirk Alan OVERHOFF, Setu RODAY, Stefanie ROEPER, Steven M. RONKIN, Rupa SAWANT, Yi SHI, Muna SHRESTHA, Marisa SPOSATO, Kathy STAVROPOULOS, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Qing TANG, Stephen THOMSON, Jinwang XU, Mariam ZAKY
  • Patent number: 10647661
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: May 12, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Nadia Ahmad, Corey Anderson, Vijayalaksmi Arumugam, Iuliana Luci Asgian, Joanne Louise Camp, Lev Tyler Dewey Fanning, Sara Sabina Hadida Ruah, Dennis Hurley, Yvonne Schmidt, David Shaw, Urvi Patel, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles
  • Publication number: 20190016671
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: July 11, 2018
    Publication date: January 17, 2019
    Inventors: Nadia AHMAD, Corey ANDERSON, Vijayalaksmi ARUMUGAM, Iuliana Luci ASGIAN, Joanne Louise CAMP, Lev Tyler Dewey FANNING, Sara Sabina HADIDA RUAH, Dennis HURLEY, Yvonne SCHMIDT, David SHAW, Urvi Jagdishbhai SHETH, Stephen Andrew THOMSON
  • Patent number: 9630956
    Abstract: The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: April 25, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Hayley Marie Binch, Dennis James Hurley, Thomas Cleveland, Pramod Joshi, Lev Tyler Dewey Fanning, Joanne Pinder, Michael O'Donnell, Anisa Nizarali Virani, Ronald Marcellus Alphonsus Knegtel, Steven John Durrant, Stephen Clinton Young, Pierre-Henri Storck, David Kay, Philip Michael Reaper, Matthew Paul Grote
  • Publication number: 20160022664
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 23, 2015
    Publication date: January 28, 2016
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Publication number: 20160022665
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 25, 2015
    Publication date: January 28, 2016
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Praveen Mudunuri, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Mark Jeffrey Sullivan, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Patent number: 9181273
    Abstract: The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: November 10, 2015
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Sara Sabina Hadida-Ruah, Hayley Marie Binch, Michael Paul DeNinno, Lev Tyler Dewey Fanning, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Nicole Hilgraf, Pramod Joshi, Edward Adam Kallel, Mark Thomas Miller, Joseph Pontillo, Alina Silina, Urvi Jagdishbhai Sheth, Dennis James Hurley, Vijayalaksmi Arumugam
  • Publication number: 20150164883
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 25, 2015
    Publication date: June 18, 2015
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Praveen Mudunuri, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Mark Jeffrey Sullivan, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokmik
  • Publication number: 20150164881
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 23, 2015
    Publication date: June 18, 2015
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Publication number: 20150025073
    Abstract: The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: August 7, 2014
    Publication date: January 22, 2015
    Inventors: Sara Sabina Hadida-Ruah, Hayley Marie Binch, Michael Paul DeNinno, Lev Tyler Dewey Fanning, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Nicole Hilgraf, Pramod Joshi, Edward Adam Kallel, Mark Thomas Miller, Joseph Pontillo, Alina Silina, Urvi Jagdishbhai Sheth, Dennis James Hurley, Vijayalaksmi ARUMUGAM
  • Patent number: 8828996
    Abstract: The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: September 9, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina Hadida-Ruah, Hayley Marie Binch, Michael Paul DeNinno, Lev Tyler Dewey Fanning, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Nicole Hilgraf, Pramod Joshi, Edward Adam Kallel, Mark Thomas Miller, Joseph Pontillo, Alina Silina, Urvi Jagdishbhai Sheth, Dennis James Hurley, Vijayalaksmi Arumugam